Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer. The Well-Shield technology is designed to detect and interpret differential metabolic responses that can indicate disease intrusion and cell malformation, including cancer.
The company aspires to improve adherence to routine medical screenings through the use of patient-friendly blood tests. Savicell Diagnostics is a majority-owned subsidiary of Savicell Corporation, a Nevada-based corporation.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Savicell Diagnostics Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jun 22, 2023
13tv.co.il
"הצלחנו להציל חיים": כך פועלת הבדיקה שמזהה סרטן בתוך 5 שעות | חדשות 13
undefined
Sep 9, 2021
www.bioworld.com
Savicell touts high accuracy results for its liquid biopsy platform
#Customers
Aug 24, 2021
www.manufacturingchemist.com
Orgenesis to collaborate with Savicell on ImmunoBiopsy platform
#Partners
Aug 29, 2019
www.timesofisrael.com
Startup says its blood test can detect early-stage lung cancer
#Customers
Jul 29, 2019
www.israel21c.org
Revolutionary blood test will detect stage 1 lung cancer